Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumor 104Advanced Solid Tumors 92Solid Tumor 69Mesothelioma 42Mesothelioma, Malignant 41Solid Tumors 37Carcinoma, Non-Small-Cell Lung 25Solid Tumor, Adult 22Stomach Neoplasms 15Ovarian Neoplasms 15Esophageal Neoplasms 15Melanoma 13Colorectal Neoplasms 13Carcinoma, Renal Cell 13Endometrial Neoplasms 11Unspecified Adult Solid Tumor, Protocol Specific 10Pancreatic Neoplasms 10Neoplasms 10Neoplasm Metastasis 10Advanced Malignant Solid Tumor 10Uterine Cervical Neoplasms 9Malignant Solid Tumor 9Lung Neoplasms 9Breast Neoplasms 9Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Sarcoma 8Advanced or Metastatic Solid Tumors 8Carcinoma, Hepatocellular 7Small Cell Lung Carcinoma 6

Interventions

fludarabine 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × HER2 Positive Advanced Solid Tumors × Other solid neoplasm × Clear all
NCT05681650 2023-12-12

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

Chinese PLA General Hospital

Phase 1/2 Recruiting
30 enrolled
Other solid neoplasm

HER2 Positive Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡